Welcome to our dedicated page for PMGC Holdings SEC filings (Ticker: ELAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
PMGC Holdings Inc. filings document material events, subsidiary announcements, capital-structure disclosures, material agreements, governance matters, and Nasdaq-listed common stock information. Recent Form 8-K reports include Regulation FD disclosures and press-release exhibits related to NorthStrive Biosciences, NorthStrive Defense Tech, AGA Precision Systems, SVM Machining, Pacific Sun Packaging, and corporate financing activity.
The company’s regulatory record identifies PMGC as a Nevada corporation with common stock listed on The Nasdaq Stock Market under the symbol ELAB and as an emerging growth company. Filing categories also cover shareholder voting matters, operating and financial results, security-structure information, and subsidiary-level developments involving manufacturing agreements, intellectual property, packaging markets, and defense technology initiatives.
PMGC Holdings Inc. (ELAB) reported that its wholly owned subsidiary NorthStrive Biosciences Inc. executed a First Amendment to its Development and License Agreement with Yuva Biosciences Inc., launching a structured three-phase Expansion Program to advance four AI-discovered small-molecule compounds toward lead nomination for Cardiac Diseases and Obesity. The amendment revises the AI Development Program definition, adds detailed concepts such as “AI Results” and “YuvaBio Platform Technology,” clarifies the Cardiac Diseases and Obesity fields of use, and adjusts associated intellectual property and financial terms. It also grants NorthStrive Biosciences a right of first refusal, during the agreement term and for one year after Phase III, to negotiate an exclusive license across the broader cardiometabolic field.
Separately, PMGC Holdings filed a Certificate of Amendment to its Articles of Incorporation increasing authorized capital stock to 1,500,000,000 shares, consisting of 1,000,000,000 common and 500,000,000 preferred shares, approved by holders representing 60.34% of the company’s voting power.
PMGC Holdings Inc. (Nasdaq: ELAB) reported several corporate actions, including effecting a previously approved 1‑for‑10 reverse stock split of its common stock on August 21, 2026. At the effective time, every 10 issued and outstanding common shares were automatically combined into 1 share, with no fractional shares issued; holders received one whole share in lieu of any fraction. Authorized capital is now 508,333,334 shares, consisting of 8,333,334 common and 500,000,000 preferred shares, and the stock continues trading on Nasdaq under the symbol ELAB on a split‑adjusted basis.
The company entered into an Exchange Agreement with Streeterville Capital LLC to exchange a Secured Pre‑Paid Purchase #2 for 80,000 common shares, leaving an outstanding balance of $1,071,339.8 on that instrument after a small partitioned amount. PMGC also signed a non‑binding term sheet with Orbit2Orbit for a three‑part relationship involving space‑based mouse studies using its EL‑22 and EL‑32 assets, a preferred U.S. manufacturing role for subsidiary A&B Aerospace, and a proposed CAD $200,000 equity subscription at CAD $0.80 per share. Separately, PMGC terminated a non‑binding LOI to acquire a 76% stake in an Arizona precision machining company after audit‑stage due diligence, incurring no breakup fee, and entered a trademark license with an affiliate of its chairman to use the “NorthStrive” marks.
PMGC Holdings Inc. reported $1.99 million in revenue for the six months ended June 30, 2026, up from none a year earlier, driven by newly acquired subsidiaries Pacific Sun Packaging, AGA Precision Systems, SVM Machining and A&B Aerospace. Gross profit was $616,165, a 30.98% gross margin.
The company recorded a larger net loss of $7.91 million from continuing operations versus $2.16 million in 2025, as operating expenses rose to $7.78 million, including higher consulting, office and administration, and professional fees. Management states that recurring losses, an accumulated deficit of $28.93 million, and operating cash outflows of $4.97 million raise substantial doubt about its ability to continue as a going concern.
Liquidity improved through financings: cash increased to $18.14 million, supported by $23.87 million of financing inflows, primarily two equity line of credit arrangements accounted for as $9.08 million of convertible debt plus $743,942 of embedded derivative liabilities. Total assets were $36.56 million and total liabilities $19.83 million, with working capital of $5.50 million. PMGC also completed the SVM and A&B Aerospace acquisitions and formed NorthStrive Defense Tech and a SPAC sponsor/vehicle to pursue future transactions.
PMGC Holdings Inc., through its wholly owned subsidiaries, entered into a Merger Agreement to combine AGA Precision Systems LLC with A&B Aerospace, Inc. AGA will merge into A&B, with A&B as the surviving entity.
All membership interests in AGA will be cancelled without consideration, while all issued and outstanding shares of A&B will remain outstanding and unchanged. The merger will be completed upon filing a Certificate of Merger with the California Secretary of State, with an anticipated effective date of July 2, 2026.
PMGC Holdings Inc., through its wholly owned subsidiary NorthStrive Defense Tech LLC, entered into a Standard Exclusive License Agreement effective June 30, 2026. The deal grants a worldwide, non-transferable, exclusive license to make, use, and sell products covered by U.S. Patent No. 12,291,334 and related know-how in aerospace and defense technologies, with rights to grant sublicenses.
NorthStrive Defense Tech must follow a development plan, provide detailed annual progress reports, and meet diligence milestones, with failure potentially constituting a material breach unless extensions are granted. Consideration includes a non-refundable license issue fee, annual maintenance fees until first Net Sales, ongoing royalties, and sublicense payments over a product- and country-specific Royalty Term that lasts until patent expiry or twelve years from first Net Sale, whichever is later.
The License Agreement includes termination rights for both parties, including nonpayment, uncured breaches, repeated payment defaults, and insolvency events. Key definitions cover Know-How, Licensed Products, Patent Rights, and Royalty Term, and the full agreement is filed as Exhibit 10.1.
PMGC Holdings Inc., through subsidiary NorthStrive Biosciences, reported positive Phase III results from its AI-driven drug discovery program with Yuva Biosciences.
Four AI-selected small molecules (C1–C4) significantly increased ANT1 protein expression in primary human skeletal muscle cells, with dose-dependent gains up to 50%. The partners plan confirmatory testing in a more mature skeletal muscle model to validate ANT1 induction as part of PMGC’s broader muscle-preservation strategy, including potential use alongside GLP-1 weight-loss treatments. The company emphasizes these in vitro findings are preliminary and subject to substantial development, regulatory and commercial risks.
PMGC Holdings Inc., which trades on Nasdaq under the symbol ELAB, reported results from its 2026 Annual Meeting and a key change to its corporate governance. Shareholders approved amended bylaws that classify the Board of Directors into two staggered classes, Class I and Class II, with different term lengths.
The staggered structure will start after the 2027 Annual Meeting. Initial Class I directors will serve until the 2030 Annual Meeting, and initial Class II directors will serve until the 2028 meeting. At the 2026 Annual Meeting, all five director nominees were elected with about 99.8% of votes cast, and shareholders also approved the staggered board proposal and ratified HTL International, LLC as auditor for the 2026 fiscal year. A quorum was present, with 6,564,834 shares represented, or 60.13% of 10,916,625 outstanding shares entitled to vote.
PMGC Holdings Inc., through its subsidiary NorthStrive Defense Tech LLC, entered into a binding term sheet with the Florida State University Research Foundation to obtain an exclusive, worldwide, sublicensable license to patent rights related to U.S. Patent No. 12,291,334 for aerospace and defense technologies. The license includes tiered earned royalties on net sales by product category and cumulative net sales, an annual minimum royalty, a sublicensing revenue share, and an annual maintenance fee, while PMGC follows a multi-year development plan that can be adjusted by mutual agreement.
NorthStrive Defense Tech also signed an Educational Research Agreement with the Florida State University Research Foundation under which it will fund $490,657 of research by the Center for Intelligent Systems, Control, and Robotics over a 12‑month term starting June 1, 2026. Any inventions made during the research will belong to the foundation, with NorthStrive Defense Tech receiving an option to negotiate a royalty-bearing license and a royalty‑free, non‑exclusive internal use license, and either party may terminate the research agreement with 30 days’ written notice.
PMGC Holdings Inc. reported that options to acquire 450,277 shares of its common stock were granted to GB Capital Ltd., an entity wholly owned by Chief Executive Officer Graydon Bensler. The non-statutory stock options have an exercise price of $1.77 per share, are 100% vested, and immediately exercisable as of June 1, 2026.
The grant was issued as partial consideration for consultant services provided to the company through GB Capital Ltd. Following this award, GB Capital Ltd. indirectly holds options covering a total of 450,279 shares of PMGC Holdings Inc. common stock.
PMGC Holdings Inc. received a Schedule 13D from Graydon Bensler and his wholly owned entity GB Capital Ltd. reporting beneficial ownership of 450,287 shares of Common Stock, representing 7.40% of the class. This total includes shares underlying options granted to GB Capital Ltd. on June 1, 2026 as partial consideration for consulting services under the company’s 2025 Equity Incentive Plan. The percentage is based on 5,631,282 shares of Common Stock issued and outstanding as of June 1, 2026. Voting and dispositive power over these shares is shared between Mr. Bensler and GB Capital Ltd.